Head-to-head evidence
Brolucizumab-Dbll vs Pegaptanib (Macugen)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Brolucizumab-Dbll
Marketed by Novartis
NCT05672979 · Phase 3 · status unknown
This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.
Pegaptanib (Macugen)
Marketed by Pfizer
NCT01100307 · Phase 3 · completed
This was a randomized, double-masked, sham-controlled phase 3 trial with 243 participants and a hard clinical visual-acuity endpoint. The primary endpoint was met: 25 of 123 participants receiving pegaptanib versus 6 of 120 receiving sham achieved at least a 10-letter improvement at week 24 (p=0.0003).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · Pegaptanib (Macugen)'s landscape